Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Xenon Pharmaceuticals Inc.XENE · Entity 2602 | EVP, Strategy & Innovation | March 11, 2024 | March 12, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Xenon Pharmaceuticals Inc.
Report date March 11, 2024 · Filed March 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.37 · Expires 2034-03-10 | Direct | 65,000 |
Reported balance
After 2024-03-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-11 · Grant · Acquired 65,000 · Balance 65,000 F1: Vesting 25% on January 1, 2025, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. |
Filing footnotes · ownership attribution and instrument terms
F1: Vesting 25% on January 1, 2025, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 11, 2024 Filed Mar 12, 2024 22:35 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $44.37 | $0.00 |
DisclosureSEC source: 0000950170-24-030233 · ownership.xml · derivative · entry 1 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Shares · 65,000 shares Expires 2034-03-10 F1 · derivative.exercise_date: Vesting 25% on January 1, 2025, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 22:31 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,407 | $0.00 Strike: $9.85 | $0.00 |
DisclosureSEC source: 0000950170-24-028795 · ownership.xml · derivative · entry 8 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 7,407 shares Expires 2024-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the "Reverse Stock Split"). The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F5 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 22:31 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,234 | $0.00 Strike: $9.85 | $0.00 |
DisclosureSEC source: 0000950170-24-028795 · ownership.xml · derivative · entry 7 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 1,234 shares Expires 2024-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the "Reverse Stock Split"). The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F5 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 22:31 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 6,118 | $46.30 | $283,263.40 |
DisclosureSEC source: 0000950170-24-028795 · ownership.xml · nonDerivative · entry 6 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,398 F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $46.25 to $46.36, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 22:31 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 1,019 | $46.15 | $47,026.85 |
DisclosureSEC source: 0000950170-24-028795 · ownership.xml · nonDerivative · entry 5 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,516 F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $46.15 to $46.17, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 22:31 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 1,289 | $45.96 | $59,242.44 |
DisclosureSEC source: 0000950170-24-028795 · ownership.xml · nonDerivative · entry 4 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,535 F2 · price: Represents the closing price of the Company's common shares on March 6, 2024 for purposes of net settlement calculations. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 22:31 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 7,407 | $9.85 | $72,958.95 |
DisclosureSEC source: 0000950170-24-028795 · ownership.xml · nonDerivative · entry 3 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the "Reverse Stock Split"). The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 22:31 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 215 | $45.96 | $9,881.40 |
DisclosureSEC source: 0000950170-24-028795 · ownership.xml · nonDerivative · entry 2 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,417 F2 · price: Represents the closing price of the Company's common shares on March 6, 2024 for purposes of net settlement calculations. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 22:31 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 1,234 | $9.85 | $12,154.90 |
DisclosureSEC source: 0000950170-24-028795 · ownership.xml · nonDerivative · entry 1 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the "Reverse Stock Split"). The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| December 29, 2023 Filed Jan 2, 2024 21:41 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | OtherCommon Shares | 8,398 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-000304 · ownership.xml · nonDerivative · entry 1 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,398 F1 · kind: Shares were transferred to the Reporting Person's former spouse pursuant to the terms of a settlement agreement dated December 29, 2023 entered into in connection with the dissolution of the Reporting Person's marriage. The Reporting Person no longer reports as beneficially owned any securities owned by his former spouse. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:46 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $34.18 | $0.00 |
DisclosureSEC source: 0001209191-23-018505 · doc4.xml · derivative · entry 1 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 75,000 shares Expires 2033-03-09 F1 · derivative.exercise_date: Vesting 25% on January 1, 2024 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 20:27 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-22-048508 · doc4.xml · derivative · entry 11 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 50,000 shares Expires 2028-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 20:27 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 8,776 | $38.80 | $340,508.80 |
DisclosureSEC source: 0001209191-22-048508 · doc4.xml · nonDerivative · entry 8 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,796 F5 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.73 to $38.88, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 20:27 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 35,103 | $38.03 | $1,334,967.09 |
DisclosureSEC source: 0001209191-22-048508 · doc4.xml · nonDerivative · entry 7 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,572 F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $37.44 to $38.35, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 20:27 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 6,121 | $38.81 | $237,556.01 |
DisclosureSEC source: 0001209191-22-048508 · doc4.xml · nonDerivative · entry 6 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,675 F3 · price: Represents the closing price of the Company's common shares on August 31, 2022 for purposes of net settlement calculations. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 20:27 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 50,000 | $4.75 | $237,500.00 |
DisclosureSEC source: 0001209191-22-048508 · doc4.xml · nonDerivative · entry 5 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,796 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2022 Filed Sep 2, 2022 20:27 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Options (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-22-048508 · doc4.xml · derivative · entry 10 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 5,000 shares Expires 2028-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| August 31, 2022 Filed Sep 2, 2022 20:27 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Options (Right to Buy) · Derivative | 17,488 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001209191-22-048508 · doc4.xml · derivative · entry 9 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 17,488 shares Expires 2022-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| August 31, 2022 Filed Sep 2, 2022 20:27 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 21,352 | $38.57 | $823,546.64 |
DisclosureSEC source: 0001209191-22-048508 · doc4.xml · nonDerivative · entry 4 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,796 F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.18 to $38.83, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 31, 2022 Filed Sep 2, 2022 20:27 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 1,572 | $37.86 | $59,515.92 |
DisclosureSEC source: 0001209191-22-048508 · doc4.xml · nonDerivative · entry 3 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,148 F1 · price: Represents the closing price of the Company's common shares on August 30, 2022 for purposes of net settlement calculations. Read SEC document |
| August 31, 2022 Filed Sep 2, 2022 20:27 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 5,000 | $4.75 | $23,750.00 |
DisclosureSEC source: 0001209191-22-048508 · doc4.xml · nonDerivative · entry 2 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2022 Filed Sep 2, 2022 20:27 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 17,488 | $2.67 | $46,692.96 |
DisclosureSEC source: 0001209191-22-048508 · doc4.xml · nonDerivative · entry 1 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 20:21 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $30.01 | $0.00 |
DisclosureSEC source: 0001209191-22-018463 · doc4.xml · derivative · entry 1 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 75,000 shares Expires 2032-03-09 F1 · derivative.exercise_date: Vesting 25% on January 1, 2023 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 00:35 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,172 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0001209191-22-017318 · doc4.xml · derivative · entry 9 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 6,172 shares Expires 2022-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. F8 · derivative.exercise_date: 25% of the shares subject to the Option vested on the one year anniversary of January 1, 2012 (the "Second 2012 Vesting Commencement Date") and thereafter 1/48th of the shares subject to the Option vest on each monthly anniversary of the Second 2012 Vesting Commencement Date F7 · derivative.expiration_date: Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 00:35 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,234 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0001209191-22-017318 · doc4.xml · derivative · entry 8 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 1,234 shares Expires 2022-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. F6 · derivative.exercise_date: 1/3 of the shares subject to the Option vested on January 1, 2012 (the "First 2012 Vesting Commencement Date") and thereafter the remaining 2/3 of the shares subject to the Option vest each monthly anniversary of the First 2012 Vesting Commencement Date over the following 4 years. F7 · derivative.expiration_date: Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 00:35 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 5,000 | $30.23 | $151,150.00 |
DisclosureSEC source: 0001209191-22-017318 · doc4.xml · nonDerivative · entry 7 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,232 F5 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.15 to $30.33, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 00:35 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 5,000 | $31.05 | $155,250.00 |
DisclosureSEC source: 0001209191-22-017318 · doc4.xml · nonDerivative · entry 6 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,232 F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.78 to $31.07, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 00:35 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 5,000 | $30.15 | $150,750.00 |
DisclosureSEC source: 0001209191-22-017318 · doc4.xml · nonDerivative · entry 5 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,232 F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.10 to $31.17, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 00:35 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 6,710 | $30.56 | $205,057.60 |
DisclosureSEC source: 0001209191-22-017318 · doc4.xml · nonDerivative · entry 4 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,232 F2 · price: Represents the closing price of the Company's common shares on March 3, 2022, which was converted to a Canadian dollar amount for purposes of net settlement calculations. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 00:35 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 6,172 | $3.67 | $22,651.24 |
DisclosureSEC source: 0001209191-22-017318 · doc4.xml · nonDerivative · entry 3 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,942 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 00:35 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 696 | $31.42 | $21,868.32 |
DisclosureSEC source: 0001209191-22-017318 · doc4.xml · nonDerivative · entry 2 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,770 F2 · price: Represents the closing price of the Company's common shares on March 3, 2022, which was converted to a Canadian dollar amount for purposes of net settlement calculations. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 00:35 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 1,234 | $3.67 | $4,528.78 |
DisclosureSEC source: 0001209191-22-017318 · doc4.xml · nonDerivative · entry 1 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,466 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 20:11 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,374 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001209191-21-036802 · doc4.xml · derivative · entry 8 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 13,374 shares Expires 2021-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F6 · derivative.exercise_date: 1/3 of the shares subject to the Option vested on March 12, 2011 (the "March 2011 Vesting Commencement Date") and thereafter the remaining 2/3 of the shares subject to the Option vest each monthly anniversary of the March 2011 Vesting Commencement Date over the following 4 years. F5 · derivative.expiration_date: Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period and a lock-up agreement period. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 20:11 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,345 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001209191-21-036802 · doc4.xml · derivative · entry 7 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 12,345 shares Expires 2021-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F4 · derivative.exercise_date: 25% of the shares subject to the Option vested on the one year anniversary of January 1, 2011 (the "January 2011 Vesting Commencement Date") and thereafter 1/48th of the shares subject to the Option vest on each monthly anniversary of the January 2011 Vesting Commencement Date. F5 · derivative.expiration_date: Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period and a lock-up agreement period. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 20:11 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 2,912 | $18.81 | $54,774.72 |
DisclosureSEC source: 0001209191-21-036802 · doc4.xml · nonDerivative · entry 6 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,232 F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $18.22 to $19.10, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 20:11 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 3,155 | $18.81 | $59,345.55 |
DisclosureSEC source: 0001209191-21-036802 · doc4.xml · nonDerivative · entry 5 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,144 F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $18.22 to $19.10, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 20:11 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 2,192 | $18.91 | $41,450.72 |
DisclosureSEC source: 0001209191-21-036802 · doc4.xml · nonDerivative · entry 4 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,299 F2 · price: Represents the closing price of the Company's common shares on May 27, 2021, which was converted to a Canadian dollar amount for purposes of net settlement calculations. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 20:11 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 13,374 | $3.85 | $51,489.90 |
DisclosureSEC source: 0001209191-21-036802 · doc4.xml · nonDerivative · entry 3 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 20:11 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 2,024 | $18.91 | $38,273.84 |
DisclosureSEC source: 0001209191-21-036802 · doc4.xml · nonDerivative · entry 2 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,117 F2 · price: Represents the closing price of the Company's common shares on May 27, 2021, which was converted to a Canadian dollar amount for purposes of net settlement calculations. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 20:11 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 12,345 | $3.76 | $46,417.20 |
DisclosureSEC source: 0001209191-21-036802 · doc4.xml · nonDerivative · entry 1 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 20:43 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $20.55 | $0.00 |
DisclosureSEC source: 0001209191-21-020481 · doc4.xml · derivative · entry 1 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Shares · 65,000 shares Expires 2031-03-11 F1 · derivative.exercise_date: Vesting 25% on January 1, 2022 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 21:40 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,230 | $0.00 Strike: $3.56 | $0.00 |
DisclosureSEC source: 0001209191-20-033669 · doc4.xml · derivative · entry 3 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 8,230 shares Expires 2020-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. F3 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2013. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3. F4 · derivative.expiration_date: Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 21:40 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 1,630 | $13.70 | $22,331.00 |
DisclosureSEC source: 0001209191-20-033669 · doc4.xml · nonDerivative · entry 2 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,796 F2 · price: Represents the closing price of the Company's common shares on May 29, 2020, which was converted to a Canadian dollar amount for purposes of net settlement calculations Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 21:40 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 8,230 | $3.56 | $29,298.80 |
DisclosureSEC source: 0001209191-20-033669 · doc4.xml · nonDerivative · entry 1 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 21:09 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $11.58 | $0.00 |
DisclosureSEC source: 0001209191-20-018963 · doc4.xml · derivative · entry 1 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Shares · 65,000 shares Expires 2030-03-11 F1 · derivative.exercise_date: Vesting 25% on January 1, 2021 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| September 16, 2019 Filed Sep 18, 2019 23:41 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $9.44 | $0.00 |
DisclosureSEC source: 0001209191-19-050166 · doc4.xml · derivative · entry 1 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Shares · 45,000 shares Expires 2029-09-15 F1 · derivative.exercise_date: Vesting over 36 months, in equal amounts, on the last day of each month. Read SEC document |
| September 12, 2019 Filed Sep 13, 2019 22:58 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,172 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001209191-19-049538 · doc4.xml · derivative · entry 3 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 6,172 shares Expires 2019-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. F3 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2012. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3. Read SEC document |
| September 12, 2019 Filed Sep 13, 2019 22:58 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 1,868 | $9.38 | $17,521.84 |
DisclosureSEC source: 0001209191-19-049538 · doc4.xml · nonDerivative · entry 2 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,196 F2 · price: Represents the closing price of the Company's common shares on September 11, 2019, which was converted to a Canadian dollar amount for purposes of net settlement calculations. Read SEC document |
| September 12, 2019 Filed Sep 13, 2019 22:58 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 6,172 | $3.07 | $18,948.04 |
DisclosureSEC source: 0001209191-19-049538 · doc4.xml · nonDerivative · entry 1 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 20:33 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,086 | $0.00 Strike: $3.77 | $0.00 |
DisclosureSEC source: 0001171843-18-002049 · formfoursherrington.xml · derivative · entry 3 ROBIN SHERRINGTON · CIK 0001619962 · EVP Bus. & Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 3,086 shares Expires 2018-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. F3 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2011. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.